Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Alector And GSK Have Announced To Dose The First Patient In PROGRESS-AD Phase 2 Trial Of AL101/GSK4527226 In Patients With Early Alzheimer's Disease

Author: Benzinga Newsdesk | February 08, 2024 08:09am

Posted In: ALEC GSK